# 1NC

## 1

#### The belief in the Western Medicinal Practices is inherently flawed and will lead to continuing oppression of the working class’s ability to resist the domination by the elite, like big pharma and those that are hastening our death.

Illich 76 (Ivan, Austrian Philosopher, Roman Catholic Priest, and “Maverick Social Critic” of the institutions of contemporary Western culture, “Medical Nemesis: The Expropriation of Health,” Pantheon Books, New York, Random House, Inc.)/DS

**The undesirable side-effects of approved, mistaken, callous, or contraindicated technical contacts with the medical system represent just the first level** of pathogenic medicine. Such clinical **[**I]atrogenesis includes not only the damage that doctors inflict with the intent of curing or of exploiting the patient, but also those other torts that result from the doctor's attempt to protect himself against the possibility of a suit for malpractice. Such attempts to avoid litigation and prosecution may now do more damage than any other iatrogenic stimulus.¶ On a second level, medical practice sponsors sickness by reinforcing a morbid society that encourages people to become consumers of curative, preventive, industrial, and environmental medicine**.** On the one hand defectives survive in increasing numbers and are fit only for life under institutional care, while on the other hand, **medically certified symptoms exempt people from industrial work and thereby remove them from the scene of political struggle to reshape the society that has made them sick. Second-level iatrogenesis finds its expression in various**¶symptoms of social overmedicalization that amount to what I shall call the expropriation of health. This second-level impact of medicine I designate as social iatrogenesis, and I shall discuss it in Part II.¶ On a third level, the so-called health professions have an even deeper, culturally health-denying effect insofar as they destroy the potential of people to deal with their human weakness, vulnerability, and uniqueness in a personal and autonomous way. The patient in the grip of contemporary medicine is but one instance of mankind in the grip of its pernicious techniques.71 This cultural iatrogenesis, which I shall discuss in Part III, is the ultimate backlash of hygienic progress and consists in the paralysis of healthy responses to suffering, impairment, and death. It occurs when people accept health management designed on the engineering model, when they conspire in an attempt to produce, as if it were a commodity, something called "better health." **This inevitably results in the managed maintenance of life** on high levels of sublethal illness. This ultimate evil of medical "progress" must be clearly distinguished from both clinical and social iatrogenesis.¶ I hope to show that on each of its three levels iatrogenesis has become medically irreversible: a feature built right into the medical endeavor. The unwanted physiological, social, and psychological by-products of diagnostic and therapeutic progress have become resistant to medical remedies. New devices, approaches, and organizational arrangements, which are conceived as remedies for clinical and social iatrogenesis, themselves tend to become pathogens contributing to the new epidemic**.** Technical and managerial measures taken on any level to avoid damaging the patient by his treatment tend to engender a self-reinforcing iatrogenic loop analogous to the escalating destruction generated by the polluting procedures used as antipollution devices.72¶ I will designate this self-reinforcing loop of negative institutional feedback by its classical Greek equivalent and call it medical nemesis. The Greeks saw gods in the forces of nature. For them, nemesis represented divine vengeance visited upon mortals who infringe on those prerogatives the gods enviously guard for themselves. Nemesis was the inevitable punishment for attempts to be a hero rather than a human being. Like most abstract Greek nouns, Nemesis took the shape of a divinity. She represented nature's response to hubris: to the individual's presumption in seeking to acquire the attributes of a god. Our contemporary hygienic hu

#### Extinction – neoliberalism/capitalism is unsustainable and the root cause of all violence and environmental destruction

Robinson 14 [William I. Robinson, Professor of Sociology, Global and International Studies, and Latin American Studies at UC-Santa Barbara, 2014, “Global capitalism and the crisis of humanity.” Cambridge University Press, https://www.cambridge.org/core/books/global-capitalism-and-the-crisis-of-humanity/5E69D07E53766BDCFBB9DF48C530267E]

Cyclical, Structural, and Systemic Crises Most commentators on the contemporary crisis refer to the “Great Recession” of 2008 and its aftermath. Yet the causal origins of global crisis are to be found in over-accumulation and also in contradictions of state power, or in what Marxists call the internal contradictions of the capitalist system. Moreover, because the system is now global, crisis in any one place tends to represent crisis for the system as a whole. The system cannot expand because the marginalisation of a significant portion of humanity from direct productive participation, the downward pressure on wages and popular consumption worldwide, and the polarisation of income, has reduced the ability of the world market to absorb world output. At the same time, given the particular configuration of social and class forces and the correlation of these forces worldwide, national states are hard-pressed to regulate transnational circuits of accumulation and offset the explosive contradictions built into the system. Is this crisis cyclical, structural, or systemic? Cyclical crises are recurrent to capitalism about once every 10 years and involve recessions that act as self-correcting mechanisms without any major restructuring of the system. The recessions of the early 1980s, the early 1990s, and of 2001 were cyclical crises. In contrast, the 2008 crisis signaled the slide into a structural crisis*. Structural crises* reflect deeper contra- dictions that can only be resolved by a major restructuring of the system. The structural crisis of the 1970s was resolved through capitalist globalisation. Prior to that, the structural crisis of the 1930s was resolved through the creation of a new model of redistributive capitalism, and prior to that the struc- tural crisis of the 1870s resulted in the development of corpo- rate capitalism. A systemic crisis involves the replacement of a system by an entirely new system or by an outright collapse. A structural crisis opens up the possibility for a systemic crisis. But if it actually snowballs into a systemic crisis – in this case, if it gives way either to capitalism being superseded or to a breakdown of global civilisation – is not predetermined and depends entirely on the response of social and political forces to the crisis and on historical contingencies that are not easy to forecast. This is an historic moment of extreme uncertainty, in which collective responses from distinct social and class forces to the crisis are in great flux. Hence my concept of global crisis is broader than financial. There are multiple and mutually constitutive dimensions – economic, social, political, cultural, ideological and ecological, not to mention the existential crisis of our consciousness, values and very being. There is a crisis of social polarisation, that is, of *social reproduction.* The system cannot meet the needs or assure the survival of millions of people, perhaps a majority of humanity. There are crises of state legitimacy and political authority, or of *hegemony* and *domination.* National states face spiraling crises of legitimacy as they fail to meet the social grievances of local working and popular classes experiencing downward mobility, unemployment, heightened insecurity and greater hardships. The legitimacy of the system has increasingly been called into question by millions, perhaps even billions, of people around the world, and is facing expanded counter-hegemonic challenges. Global elites have been unable counter this erosion of the system’s authority in the face of worldwide pressures for a global moral economy. And a canopy that envelops all these dimensions is a crisis of sustainability rooted in an ecological holocaust that has already begun, expressed in climate change and the impending collapse of centralised agricultural systems in several regions of the world, among other indicators. By a crisis of humanityI mean a crisis that is approaching systemic proportions, threatening the ability of billions of people to survive, and raising the specter of a collapse of world civilisation and degeneration into a new “Dark Ages.”2 This crisis of humanity shares a number of aspects with earlier structural crises but there are also several features unique to the present: 1. The system is fast reaching the ecological limits of its reproduction. Global capitalism now couples human and natural history in such a way as to threaten to bring about what would be the sixth mass extinction in the known history of life on earth.3 This mass extinction would be caused not by a natural catastrophe such as a meteor impact or by evolutionary changes such as the end of an ice age but by purposive human activity. According to leading environmental scientists there are nine “planetary boundaries” crucial to maintaining an earth system environment in which humans can exist, four of which are experiencing at this time the onset of irreversible environmental degradation and three of which (climate change, the nitrogen cycle, and biodiversity loss) are at “tipping points,” meaning that these processes have already crossed their planetary boundaries. 2. The magnitude of the means of violence and social control is unprecedented, as is the concentration of the means of global communication and symbolic production and circulation in the hands of a very few powerful groups. Computerised wars, drones, bunker-buster bombs, star wars, and so forth, have changed the face of warfare. Warfare has become normalised and sanitised for those not directly at the receiving end of armed aggression. At the same time we have arrived at the panoptical surveillance society and the age of thought control by those who control global flows of communication, images and symbolic production. The world of Edward Snowden is the world of George Orwell; *1984 has arrived;* 3. Capitalism is reaching apparent limits to its extensive expansion. There are no longer any new territories of significance that can be integrated into world capitalism, de-ruralisation is now well advanced, and the commodification of the countryside and of pre- and non-capitalist spaces has intensified, that is, converted in hot-house fashion into spaces of capital, so that *intensive* expansion is reaching depths never before seen. Capitalism must continually expand or collapse. How or where will it now expand? 4. There is the rise of a vast surplus population inhabiting a “planet of slums,”4 alienated from the productive economy, thrown into the margins, and subject to sophisticated systems of social control and to destruction - to a mortal cycle of dispossession-exploitation-exclusion. This includes prison-industrial and immigrant-detention complexes, omnipresent policing, militarised gentrification, and so on; 5. There is a disjuncture between a globalising economy and a nation-state based system of political authority. Transnational state apparatuses are incipient and have not been able to play the role of what social scientists refer to as a “hegemon,” or a leading nation-state that has enough power and authority to organise and stabilise the system. The spread of weapons of mass destruction and the unprecedented militarisation of social life and conflict across the globe makes it hard to imagine that the system can come under any stable political authority that assures its reproduction. Global Police State How have social and political forces worldwide responded to crisis? The crisis has resulted in a rapid political polarisation in global society. Both right and left-wing forces are ascendant. Three responses seem to be in dispute. One is what we could call “reformism from above.” This elite reformism is aimed at stabilising the system, at saving the system from itself and from more radical re- sponses from below. Nonetheless, in the years following the 2008 collapse of the global financial system it seems these reformers are unable (or unwilling) to prevail over the power of transnational financial capital. A second response is popular, grassroots and leftist resistance from below. As social and political conflict escalates around the world there appears to be a mounting global revolt. While such resistance appears insurgent in the wake of 2008 it is spread very unevenly across countries and regions and facing many problems and challenges. Yet another response is that I term *21st century fascism*.5 The ultra-right is an insurgent force in many countries. In broad strokes, this project seeks to fuse reactionary political power with transnational capital and to organise a mass base among historically privileged sectors of the global working class – such as white workers in the North and middle layers in the South – that are now experiencing heightened insecurity and the specter of downward mobility. It involves militarism, extreme masculinisation, homophobia, racism and racist mobilisations, including the search for scapegoats, such as immigrant workers and, in the West, Muslims. Twenty-first century fascism evokes mystifying ideologies, often involving race/culture supremacy and xenophobia, embracing an idealised and mythical past. Neo-fascist culture normalises and glamorises warfare and social violence, indeed, generates a fascination with domination that is portrayed even as heroic.

#### Thus, the role of the ballot is to unconditionally resist neoliberalism/capitalism

#### The alternative is to reject the aff in favor of organizing toward the Communist Party – only the Party can provide effective accountability mechanisms to correct unproductive tendencies, educate and mobilize marginalized communities, and connect local struggles to a movement for international liberation –

**Escalante 18**  
(Alyson Escalante is a Marxist-Leninist, Materialist Feminist and Anti-Imperialist activist. “PARTY ORGANIZING IN THE 21ST CENTURY” September 21st, 2018 <https://theforgenews.org/2018/09/21/party-organizing-in-the-21st-century/> cVs)

I would argue that within the base building movement, there is a move towards party organizing, but this trend has not always been explicitly theorized or forwarded within the movement. My goal in this essay is to argue that base building and dual power strategy can be best forwarded through party organizing, and that party organizing can allow this emerging movement to solidify into a powerful revolutionary socialist tendency in the United States. One of the crucial insights of the base building movement is that the current state of the left in the United States is one in which revolution is not currently possible. There exists very little popular support for socialist politics. A century of anticommunist propaganda has been extremely effective in convincing even the most oppressed and marginalized that communism has nothing to offer them. The base building emphasis on dual power responds directly to this insight. By building institutions which can meet people’s needs, we are able to concretely demonstrate that communists can offer the oppressed relief from the horrific conditions of capitalism. Base building strategy recognizes that actually doing the work to serve the people does infinitely more to create a socialist base of popular support than electing democratic socialist candidates or holding endless political education classes can ever hope to do. Dual power is about proving that we have something to offer the oppressed. The question, of course, remains: once we have built a base of popular support, what do we do next? If it turns out that establishing socialist institutions to meet people’s needs does in fact create sympathy towards the cause of communism, how can we mobilize that base? Put simply: in order to mobilize the base which base builders hope to create, we need to have already done the work of building a communist party. It is not enough to simply meet peoples needs. Rather, we must build the institutions of dual power in the name of communism. We must refuse covert front organizing and instead have a public face as a communist party. When we build tenants unions, serve the people programs, and other dual power projects, we must make it clear that we are organizing as communists, unified around a party, and are not content simply with establishing endless dual power organizations. We must be clear that our strategy is revolutionary and in order to make this clear we must adopt party organizing. By “party organizing” I mean an organizational strategy which adopts the party model. Such organizing focuses on building a party whose membership is formally unified around a party line determined by democratic centralist decision making. The party model creates internal methods for holding party members accountable, unifying party member action around democratically determined goals, and for educating party members in communist theory and praxis. A communist organization utilizing the party model works to build dual power institutions while simultaneously educating the communities they hope to serve. Organizations which adopt the party model focus on propagandizing around the need for revolutionary socialism. They function as the forefront of political organizing, empowering local communities to theorize their liberation through communist theory while organizing communities to literally fight for their liberation.

A party is not simply a group of individuals doing work together, but is a formal organization unified in its fight against capitalism. Party organizing has much to offer the base building movement. By working in a unified party, base builders can ensure that local struggles are tied to and informed by a unified national and international strategy. While the most horrific manifestations of capitalism take on particular and unique form at the local level, we need to remember that our struggle is against a material base which functions not only at the national but at the international level. The formal structures provided by a democratic centralist party model allow individual locals to have a voice in open debate, but also allow for a unified strategy to emerge from democratic consensus. Furthermore, party organizing allows for **local organizations and individual** organizers to be held accountable for their actions. It allows criticism to function not as one independent group criticizing another independent group, but rather as comrades with a formal organizational unity working together to sharpen each others strategies and to help correct chauvinist ideas and actions. In the context of the socialist movement within the United States, such accountability is crucial. As a movement which operates within a settler colonial society, imperialist and colonial ideal frequently infect leftist organizing. Creating formal unity and party procedure for dealing with and correcting these ideas allows us to address these consistent problems within American socialist organizing. Having a formal party which unifies the various dual power projects being undertaken at the local level also allows for base builders to not simply meet peoples needs, but to pull them into the membership of the party as organizers themselves. The party model creates a means for sustained growth to occur by unifying organizers in a manner that allows for skills, strategies, and ideas to be shared with newer organizers. It also allows community members who have been served by dual power projects to take an active role in organizing by becoming party members and participating in the continued growth of base building strategy. It ensures that there are formal processes for educating communities in communist theory and praxis, and also enables them to act and organize in accordance with their own local conditions. We also must recognize that the current state of the base building movement precludes the possibility of such a national unified party in the present moment. Since base building strategy is being undertaken in a number of already established organizations, it is not likely that base builders would abandon these organizations in favor of founding a unified party. Additionally, it would not be strategic to immediately undertake such complete unification because it would mean abandoning the organizational contexts in which concrete gains are already being made and in which growth is currently occurring. What is important for base builders to focus on in the current moment is building dual power on a local level alongside building a national movement. This means aspiring towards the possibility of a unified party, while pursuing continued local growth. The movement within the Marxist Center network towards some form of unification is positive step in the right direction. The independent party emphasis within the Refoundation caucus should also be recognized as a positive approach. It is important for base builders to continue to explore the possibility of unification, and to maintain unification through a party model as a long term goal. In the meantime, individual base building organizations ought to adopt party models for their local organizing. Local organizations ought to be building dual power alongside recruitment into their organizations, education of community members in communist theory and praxis, and the establishment of armed and militant party cadres capable of defending dual power institutions from state terror. Dual power institutions must be unified openly and transparently around these organizations in order for them to operate as more than “red charities.” Serving the people means meeting their material needs while also educating and propagandizing. It means radicalizing, recruiting, and organizing. The party model remains the most useful method for achieving these ends. The use of the party model by local organizations allows base builders to gain popular support, and most importantly, to mobilize their base of popular support towards revolutionary ends, not simply towards the construction of a parallel economy which exists as an end in and of itself. It is my hope that we will see future unification of the various local base building organizations into a national party, but in the meantime we must push for party organizing at the local level. If local organizations adopt party organizing, it ought to become clear that a unified national party will have to be the long term goal **of the base building movement.** Many of the already existing organizations within the base building movement already operate according to these principles. I do not mean to suggest otherwise. Rather, my hope is to suggest that we ought to be explicit about the need for party organizing and emphasize the relationship between dual power and the party model. Doing so will make it clear that the base building movement is not pursuing a cooperative economy alongside capitalism, but is pursuing a revolutionary socialist strategy capable of fighting capitalism. The long term details of base building and dual power organizing will arise organically in response to the conditions the movement finds itself operating within. I hope that I have put forward a useful contribution to the discussion about base building organizing, and have demonstrated the need for party organizing in order to ensure that the base building tendency maintains a revolutionary orientation. The finer details of revolutionary strategy will be worked out over time and are not a good subject for public discussion. I strongly believe party organizing offers the best path for ensuring that such strategy will succeed. My goal here is not to dictate the only possible path forward but to open a conversation about how the base building movement will organize as it transitions from a loose network of individual organizations into a unified socialist tendency. These discussions and debates will be crucial to ensuring that this rapidly growing movement can succeed.

## 2

#### Interp: the affirmative debater must defend the member nations of the wto ought to reduce intellectual property for medicines

#### Violation: its extra topical. 1. they use msf guidelines which is not a part of the wto

#### Standards: -- Limits: 1. Infinite amount of affs that are created through different organizations which means the impacts to the aff can be infinite and always ow. 2. infinite amount of planks to generate solvency on every possible args creates a perfect unbeatable 1ac. 3. Ground: Kills neg ground since we would have to predict literally every mechanism that ever existed and prep it out which is impossible and would lead to stale debates. And generics don’t solve because these affs are specific

#### 4. Clash: kills clash because of unpredictability and we can’t properly engage with the aff

#### Voters: Fairness is a voter because a] no one would join debate if it’s unfair because debate is a game, we play to win b] turns education - an unfair debate is inherently uneducational because the round is skewed from the start. Use competing interps: Competing interpretations over reasonability: a] creates a race to the top where we find best norm for debate that allow us to clash b] reasonability creates arbitrary britelines which leads to judge intervention and causes a race to the bottom where we read increasingly unfair practices that barely fit the bright line. Drop the debater – key to deterring future abuse and drop the arg is their advocacy text so they lose anyway No rvis. 1. Chilling effect – really good theory debaters get bait theory by prepping abusive positions. 2. Illogical – u don’t win for being fair

## 3

#### CP Text: Member nations of the WTO should implement price controls on medicines

#### Solves the aff by making medicines more accessible and reducing prices

## 4

#### Biotech is the new frontier; America is ahead but China is dangerously close

Gupta 6/11 [Gaurav Gupta, Biotech Investor, Founder of Ascendant BioCapital, a life science investment firm based in New York. Previously, Gaurav worked at OrbiMed Advisors, and served as a resident in neurological surgery at Columbia University Medical Center. He has co-authored over a dozen articles in peer-reviewed journals, filed a patent on a device for use in spine surgery, and edited a book on the technical and ethical implications of using tissue engineered products in the operating room. Dr. Gupta obtained his M.D. from the Stanford University School of Medicine, where he was a Paul and Daisy Soros Fellow, and B.S. and M.S.E. in biomedical engineering from Johns Hopkins University, where he was a Charles R. Westgate Scholar.) “As Washington Ties Pharma’s Hands, China Is Leaping Ahead” Barron’s Magazine: Commentary, China., 6/11/2021] RM

There should be no doubt that we are living at the dawn of a golden age of biomedical innovation. The American scientific engine that produced Covid-19 vaccines in record time was fueled by a convergence of advances in genomics, biomarkers, data science, and manufacturing years in the making. The first Food and Drug Administration approvals of a host of new product formats—oligonucleotide, bispecific, oncolytic virus, CAR-T, and lentivirus/AAV—all took place within the last decade. These represent an unprecedented expansion of the armamentarium that physicians have at their disposal to treat and cure disease. In the last few years, [47% of all new medicines](https://www.efpia.eu/media/554521/efpia_pharmafigures_2020_web.pdf) were invented by U.S. biopharma companies, with [homegrown startups](https://www.cbo.gov/publication/57126) driving the majority of innovation. The bulk of the remainder were developed by foreign companies specifically for the U.S. market.

An indirect benefit of these trends is that most novel therapeutics undergo clinical development and early commercial launch here in the U.S. The rest of the world understands that the American patient has earlier and broader access to groundbreaking therapies via these mechanisms. Indeed, the past decade is filled with examples of medical “firsts” for American patients: the first cure for Hepatitis C, the first gene therapy for blindness, the first immunotherapy for cancer. Future rewards will be greater still if we preserve our current system of incentivizing and protecting innovation.

The remarkable innovation capacity of our biopharmaceutical industry ought to be a source of national pride. Yet while “Made in America” is the global standard for medicines in development today, misguided policy risks ceding our scientific prowess to other countries in the future. This is particularly true in the case of China, where biotechnology has become a strategic pillar for the health of its people and economy.

From 2016 to 2020, the market capitalization of all Chinese biopharma companies increased exponentially from [$1 billion to over $200 billion](https://www.bloomberg.com/news/articles/2021-03-01/xi-mobilizes-china-for-tech-revolution-to-cut-dependence-on-west). China saw over [$28 billion](https://www.bioworld.com/articles/506978-china-sees-five-year-highs-in-life-sciences-investments-and-partnering) invested in its life sciences sector in 2020, double the previous year’s amount. Returns on China’s investment are already arriving. The FDA approved a drug developed in China for the first time ever in 2019. While China’s innovation capacity currently remains behind America’s, my experiences as a biopharma professional make it clear they are doing everything they can to catch up and catch up fast.

In fact, when I speak to Chinese biotechnology executives, they boast that they can run clinical trials faster than their U.S. counterparts. The danger of misguided policies that disincentivize pharmaceutical innovation in the U.S. is effectively driving that same innovation to China. If we close off the market in the U.S. at the same time that China is opening its market to innovative new products, then we will see companies choose to first launch impactful novel medicines in China, based on clinical trials conducted in China. Because the FDA rarely accepts data generated entirely outside the U.S., this relocation of research capacity will negatively affect Americans’ access to cutting-edge therapies.

The biotechnology field is advancing rapidly. Promising technologies such as targeted protein degradation and gene editing are perhaps not far from being developed into impactful medicines, and the U.S. risks these technologies being mastered by Chinese companies.

It is widely held that allowing China to gain an asymmetric edge in critical technologies such as AI or quantum computing could destabilize the geopolitical balance of power. The same is true of biotechnology. Chinese scientists were the first to edit the genomes of human embryos, in [contravention](https://www.sciencemag.org/news/2019/12/chinese-scientist-who-produced-genetically-altered-babies-sentenced-3-years-jail) of international standards, and the U.S. national security community believes China is [pushing ahead](https://www.nbcnews.com/politics/national-security/china-has-done-human-testing-create-biologically-enhanced-super-soldiers-n1249914) with experimental concepts for biological and cognitive enhancement of soldiers and civilians. American policy should be focused on protecting, rather than undermining, the global dominance of our biotechnology industry.

#### The plan recapitulates IP to China, destroying competitive advantages

WSJ 5/6 [Wall Street Journal Editorial Board, WSJ Opinion Philosophy: “We speak for free markets and free people, the principles, if you will, marked in the watershed year of 1776 by Thomas Jefferson's Declaration of Independence and Adam Smith's “Wealth of Nations.” So over the past century and into the next, the Journal stands for free trade and sound money; against confiscatory taxation and the ukases of kings and other collectivists; and for individual autonomy against dictators, bullies and even the tempers of momentary majorities.” Edited by Paul A. Gigot and Daniel Henninger, “Biden’s Vaccine IP Debacle: His patent heist is a blow to the Covid fight and U.S. biotech.” The WSJ Opinion: Review and Outlook, May 6, 2021] RM

We’ve already criticized President Biden’s bewildering decision Wednesday to endorse a patent waiver for Covid vaccines and therapies. But upon more reflection this may be the single worst presidential economic decision since Nixon’s wage-and-price controls.

In one fell swoop he has destroyed tens of billions of dollars in U.S. intellectual property, set a destructive precedent that will reduce pharmaceutical investment, and surrendered America’s advantage in biotech, a key growth industry of the future. Handed an American triumph of innovation and a great soft-power opportunity, Mr. Biden throws it all away.

\*\*\*

India and South Africa have been pushing to suspend patents at the World Trade Organization for months. They claim that waiving IP protections for Covid vaccines and therapies is necessary to expand global access, but their motivation is patently self-interested.

Both are large producers of generic drugs, though they have less expertise and capacity to make complex biologics like mRNA vaccines. They want to force Western pharmaceutical companies to hand over IP free of charge so they can produce and export vaccines and therapies for profit. Their strategy has been to shame Western leaders into surrendering with the help of Democrats in the U.S.

But suspending IP isn’t necessary to expand supply and will impede safe vaccine production. The global vaccine supply is already increasing rapidly thanks to licensing agreements the vaccine makers have made with manufacturers around the world.

Pfizer and BioNTech this week said they aimed to deliver three billion doses this year, up from last summer’s 1.2 billion estimate. Moderna increased its supply forecast for this year to between 800 million and a billion from 600 million. AstraZeneca says it has built a supply network with 25 manufacturing organizations in 15 countries to produce three billion doses this year.

AstraZeneca and Novavax have leaned heavily on manufacturers in India to produce billions of doses reserved for lower-income countries. But India has restricted vaccine exports to supply its own population. IP simply isn’t restraining vaccine production.

Busting patents also won’t speed up production, since it would take months for these countries to set up new facilities. Competition will increase for scarce ingredients, and less efficient manufacturers with little expertise would make it harder for licensed partners to produce vaccines.

There’s also the problem of safety. Johnson & Johnson has experienced quality problems at an Emergent plant making its vaccines, and that’s in Baltimore. Imagine the potential problems with unlicensed producers in, say, Malaysia or Brazil. If vaccines made there have complications, confidence in licensed vaccines could plummet too. And who would Pfizer and Moderna sue to get their reputations back?

The economic self-damage is also hard to fathom. The U.S. currently has a competitive advantage in biotech and biologics manufacturing, which could be a growing export industry. Waiving IP protections for Covid vaccines and medicines will give away America’s crown pharmaceutical jewels and make the U.S. and world more reliant on India and China for pharmaceuticals.

Moderna has been working on mRNA vaccines for a decade. Covid represents its first success. Ditto for Novavax, which has been at it for three decades. Small biotech companies in the U.S. have been studying how to create vaccines using nasal sprays, pills and patches.

Thanks to Mr. Biden, all this could become the property of foreign governments. Licensing agreements allow developers to share their IP while maintaining quality control. Breaking patents and forcing tech transfers will enable China and low-income countries to manufacture U.S. biotech products on their own.

China’s current crop of vaccines are far less effective than those in the West, but soon Beijing might be able to purvey Pfizer knock-offs. The U.S. has spent years deploring China’s theft of American IP, and now the Biden Administration may voluntarily let China could reap profits from decades of American innovation.

\*\*\*

Instead of handing over American IP to the world, Mr. Biden could negotiate bilateral vaccine agreements and export excess U.S. supply. If Mr. Biden wants to increase global supply safely, the U.S. could spend more to help the companies produce more for export. Then the jobs would go to Americans. We thought this was the point of the production deal Mr. Biden negotiated between J&J and Merck.

Alas, this President seems to be paying more attention these days to Elizabeth Warren, Bernie Sanders, Alexandria Ocasio-Cortez and Nancy Pelosi. They think vaccines and new drugs can be conjured by government as a public good with no incentive for risk-taking or profit. This really is destructive socialism.

Mr. Biden ought to listen to Angela Merkel. Pfizer’s partner BioNTech is a German firm, and the German Chancellor said Thursday that she opposes the WTO heist: “The protection of intellectual property is a source of innovation and it must remain so in the future.”

At least IP is safe in Germany. Mr. Biden has sent a signal around the world that nobody’s intellectual property is safe in America.

#### China biotech heg causes a laundry list of impacts

Moore 19 Scott Moore - Director of the Penn Global China Program at the University of Pennsylvania, Young Professional and Water Resources Management Specialist at the World Bank Group, and Environment, Science, Technology, and Health Officer for China at the U.S. Department of State, Giorgio Ruffolo Post-Doctoral Research Fellow with the Belfer Center for Science and International Affairs at Harvard University, Truman, Fulbright, and Rhodes Scholar., Foreign Policy, "China's Genetic Experiments Are Pushing Ethical Limits", NOVEMBER 8, 2019, 2:53 PM, https://foreignpolicy.com/2019/11/08/cloning-crispr-he-jiankui-china-biotech-boom-could-transform-lives-destroy-them/ - BD

When James Clapper, the U.S. director of national intelligence at the time, appeared before Congress in early January 2016 for an annual briefing of threats to the United States, he didn’t lack for material. Just a few weeks earlier, North Korea had tested a nuclear device, and Russia had begun deploying cruise missiles that appeared to violate a crucial arms-control agreement. But to the surprise of many experts, Clapper devoted a good chunk of his time to describing a much more exotic threat: biomedical research. Specifically, Clapper warned, “Research in genome editing conducted by countries with different regulatory or ethical standards than those of Western countries probably increases the risk of the creation of potentially harmful biological agents or products.”

Clapper’s statement didn’t explicitly mention China—but it didn’t need to. As his testimony went on to make clear, while in the 20th century the United States and Soviet Union held the keys to preventing planetary catastrophe, in the 21st the principal players are the United States and China. And while in a previous age keeping Pandora’s box closed meant preventing nuclear war, today it’s about preventing biotech dangers.

In just the past few years, the development of inexpensive gene-editing techniques has democratized biomedical research, producing a biotech bonanza in places such as China and creating a whole new category of security threats in the process, from the use of genetic information to persecute dissidents and minority groups to the development of sophisticated bioweapons.

When it comes to the United States, China, and technology, artificial intelligence tends to grab most of the attention. But policymakers need to come to grips with the even bigger threat of biotechnology—and soon. Fortunately, though, shared concerns about China’s role in biotechnology also provide a rare chance for meaningful and productive engagement in shaping the rules of a new world.

China’s starring role in preventing the 21st century’s biotech perils stems from its skyrocketing investment in biomedical research. Historically, Western countries, and especially the United States, have been the epicenter of research in the life sciences. The United States alone accounted for some 45 percent of biotech and medical patents filed in the 14-year period ending in 2013. But now, thanks to heavy state-backed investment, China is catching up. Economic plans instituted in 2015 call for the biotechnology sector to account for more than 4 percent of China’s total GDP by 2020, and estimates suggest that as of 2018, central, provincial, and local governments had already invested over $100 billion in the life sciences. Chinese venture capital and private equity investment in the life sciences, meanwhile, totaled some $45 billion just from 2015 to 2017.

China has also invested considerable effort in competing with countries like the United States for biotech talent. Of some 7,000 researchers recruited under the Thousand Talents Plan since 2008, more than 1,400 specialized in the life sciences. A leading American geneticist, Harris Lewin, has warned that the United States is “starting to fall behind … the Chinese, who have always been good collaborators, [are] now taking the lead.”

For the United States and other Western countries, China’s growing role in biomedical research is raising plenty of concern. Several Chinese researchers have shown a willingness to ignore ethical and regulatory constraints on genetic research. In 2018, He Jiankui became a poster child for scientific irresponsibility when he announced he had edited the genes of two twins in utero without following basic safety protocols. He reportedly dismissed them as guidelines, not laws.

Yet the reaction at home was not what He had hoped for. His research had been made possible by the relatively lax standards of Chinese universities, even as he had kept the true nature of it secret from many involved – while discussing it with a small group of Western bioethicists and scientists, who stressed their disapproval. It’s not uncommon in China to break the rules and be lauded for the results anyway, whatever the field. For He, though, the vast international attention that came after the story broke cost him his career and possibly his freedom. Chinese media rushed to stress official disapproval of the experiments. Even the overt purpose of the editing – to ensure that the babies, born to HIV+ mothers, enjoyed protection against the virus – turned out to be scientifically weak.

As China’s biotech sector grows, so too do fears that Chinese researchers like He will be more willing to push the limits of both science and ethics than those in the United States. Earlier this year, Chinese researchers recorded another mind-bending milestone when they implanted human genes linked to intelligence into monkey embryos—and then said that the monkeys performed better on memory tests.

The dominance of the party-state in China raises serious concerns around biotechnology, especially because it carries increasingly ethnonationalist tone. When in 2018 Chinese researchers created the world’s first primate clones, for example, they dubbed them Zhong Zhong and Hua Hua, from the term zhonghua meaning “The Chinese Nation”—an oddly jingoistic moniker for a pair of monkeys. Chinese government policies often blur the line between eugenics and education, lumped together as improving the “quality” (suzhi) of the population, which received another stamp of official endorsement following the recent Fourth Plenum. These programs are carried out through the country’s huge so-called family planning bureaucracy—originally established to enforce the one-child policy.

Moreover, Beijing is increasingly extending its formidable social control apparatus into the realm of genetics. While there are considerable restrictions on private firms sharing biomedical data, largely because of an ugly history of popular discrimination against hepatitis carriers, the government has no such restrictions. A New York Times report earlier this year suggested, for example, that Chinese authorities had assembled a vast trove of genetic data on Chinese citizens without their consent, with the Uighur minority group having been specifically targeted.

Beijing’s brand of bio-nationalism also directly threatens the United States. U.S. officials have been warning universities and research institutions that the biotech sector is a focal point for Chinese industrial espionage activities in the United States. And this past August, a senior Defense Department official warned Congress that China’s growing role in pharmaceutical manufacturing could allow it to disrupt deliveries of critical battlefield medicines, or potentially even alter them to harm U.S. forces

Yet the biggest risks posed by biotech, for China, the United States, and other countries, pertain to nonstate actors. A critical feature of modern biotech, in contrast to technology like nuclear weapons, is that it’s cheap and easy to develop. A technique known as CRISPR, which the Chinese researcher He used in his illicit gene-editing work, makes it practical for just about anyone to manipulate the genomes of just about any organism they can lay their hands on. CRISPR makes it much simpler to skirt ethical restrictions and terrifyingly straightforward for terrorist groups to develop fearsome biological weapons.

Researchers have already shown it’s possible to reconstruct the smallpox virus, which was eradicated in the real world in the 1970s, for as little as $200,000 using DNA fragments you can order online. If a terrorist or rogue state were to successfully do so, virtually no one alive would have any resistance to the virus—and most stockpiles of the vaccine were destroyed long ago. There is an organization, the International Gene Synthesis Consortium, that tries to screen suspicious orders for DNA fragments that might be used to build such bioweapons. And while most of the world’s major DNA synthesis firms belong to the consortium, membership is completely voluntary, and there’s also a thriving and entirely unregulated black market—much of it based in China.

All of this means that biosecurity standards in places like China matter more than ever. After all, if a major bioweapon were to be unleashed, it’s unlikely that any major, globally integrated country could escape unharmed. Fortunately, there are growing signs China is open to better regulation of its biotech sector. In February, the Chinese government announced that “high risk” biomedical research would be overseen by the State Council, China’s equivalent of the cabinet—a sign of the concern with which Beijing views incidents like the He Jiankui CRISPR scandal. In a further sign of this concern, in August, the Chinese Communist Party announced the creation of a new committee to advise top leaders on research ethics.

Government worry is matched by growing public concern within China. Opposition to genetically modified organisms is arguably stronger in China than in the West, and health concerns top the list of public issues. Rumors and panics largely center around health issues, especially after a series of vaccination scandals. That means that the government has to walk unusually carefully and offers plenty of scope to build ethical concerns into both law and practice.

There are plenty of issues for U.S.-China cooperation on biotechnology and biosecurity to address. Given China’s role in the He Jiankui scandal, meanwhile, it would make sense to partner with the United States and other countries as part of a new World Health Organization effort to set international guidelines for the use of CRISPR. Another promising area of U.S.-China cooperation, especially in the research community, relates to so-called gene drives, the process of editing genomes and then spreading them through an entire population in just a few generations. Using gene drives to prevent select mosquito species from reproducing, for example, might finally banish the world of debilitating, widespread diseases such as malaria and Zika, while endangered species might be engineered to survive climate change.

Microsoft founder Bill Gates once observed that “The world hasn’t had that many technologies that are both promising and dangerous. … We had nuclear weapons and nuclear energy.” But thanks in large part to the efforts of biomedical researchers in the United States and China, biotechnology is opening a similar Pandora’s box. And while the world has so far avoided nuclear war or conflict, it’s done so largely though efforts by governments, aided by the fact that nuclear technology is extremely difficult and expensive to master.

The new wave of synthetic biology is exactly the opposite: It’s cheap to use and employ. For that very reason, while the U.S., Chinese, and other governments will be critical to dealing with the threat of new technologies, the discussions can’t be limited to nation-states. They’ll also have to gather together individual researchers, institutions, companies, and organizations like the International Gene Synthesis Consortium. When it comes to the risks posed by emerging technologies, Beijing, like Washington, will have to face the limits of its ability to solve the problem on its own.

#### China will leapfrog the US through biotech primacy

Cumbers 20 [John Cumbers, “I am the founder and CEO of SynBioBeta, the leading community of innovators, investors, engineers, and thinkers who share a passion for using synthetic biology to build a better, more sustainable universe. I publish the weekly SynBioBeta Digest, host the SynBioBeta Podcast, and wrote “What’s Your Biostrategy?”, the first book to anticipate how synthetic biology is going to disrupt virtually every industry in the world. I also founded BetaSpace, a space settlement innovation network and community of visionaries, technologists, and investors accelerating the industries needed to sustain human life here and off-planet. I’ve been involved with multiple startups, I am an operating partner and investor at the hard tech investment fund Data Collective, and I'm a former bioengineer at NASA. I earned my PhD in Molecular Biology, Cell Biology, and Biochemistry from Brown University and am originally from the UK.”) “China’s Plan To Beat The U.S. In The Trillion-Dollar Global Bioeconomy” Forbes, 2/3/2020] RM

The report, entitled “Safeguarding the Bioeconomy,” looks at how research and innovation in the life sciences is driving rapid growth in agriculture, biomedical science, information science and computing, energy, and other sectors of the U.S. economy. This economic activity—collectively referred to as the bioeconomy—presents many opportunities to create jobs, improve the quality of life, and continue to drive the U.S. economy as a whole.

The report says that while the U.S. has been a leader in advancements in the biological sciences, other countries are actively investing in and expanding their capabilities in this area—and the U.S.’s lead is beginning to slip.

Four reasons everyone should care about the U.S. bioeconomy

It might be easy for some to dismiss the report out of hand as a bunch of alarmist professors lobbying for more research money. But when you consider all the ways that biotechnology powers the economy and impacts our daily lives, it becomes clear that this is about something more:

The economy: at $1 trillion in value, the U.S. bioeconomy represents hundreds of thousands of quality, high-paying jobs for Americans.

Health & medicine: innovators in the bioeconomy are making next-generation therapies for cancer and diabetes, tackling emerging diseases like Coronavirus, and even increasing human longevity.

Food & farming: biotechnology is not only making agriculture more sustainable, it’s also bringing to market new and improved crops that are more nutritious, more affordable, and more delicious.

The environment: humanity’s health and well-being depend on our ability to stop and reverse climate change, and we can’t do it without biological solutions that treat carbon not as a waste product, but as the starting point for chemicals and materials that today use petroleum.

Considering all this, it doesn’t seem like an overstatement when the report authors say that U.S. competitiveness in the bioeconomy is key to maintaining the economic health and security of the country.

The very real risks to the U.S. bioeconomy

There are many things that can go wrong, causing the U.S. to lose its current edge in the global bioeconomy. Some of these are economic risks, and others present serious national security risks. All of them are related to a failure of our government to act now. Here’s a sampling of the risks to U.S. leadership at the frontiers of tech and bio:

Insufficient government R&D investment. Money for basic research and development builds the foundations of the bioeconomy. We learn, achieve new results, and create new applications. Investments that help develop enabling tools, technologies, and standards have the potential to maintain the U.S. bioeconomy competitive in a global bioeconomy.

Ineffective or inefficient regulations. Regulatory uncertainty stifles creative new approaches that may have unknown paths, long delays, or that might be prohibited by later changes.

Inadequate workforce. The U.S.’s K-12 education system may not prepare students to study STEM subjects at the university and postgraduate level, hindering the quality of workers. A skilled workforce gives U.S. companies the best talent to choose from, and it also encourages international firms to establish research and production facilities here.

Ineffective or inefficient intellectual property protections. Uncertainty over what is patentable could discourage innovators who are considering whether and how to bring their innovations to market. Patent eligibility is also important to venture capitalists and private equity investors when considering whether to invest in biotechnology companies.

Cybersecurity. As biological engineering depends more and more on massive datasets, the emerging bioeconomy now exists at the intersection of information science and biotechnological science. The bioeconomy’s growing reliance on software, networking, and computer hardware tools yields the same cyber vulnerabilities present in any other sector, including hacking, sabotage, breached privacy, or theft of intellectual property.

Biosafety and biosecurity risks. The tools of today’s bioeconomy are enabling new capabilities that can generate concerns regarding traditional biothreats. These can include the accidental or intentional creation or release of dangerous or lethal pathogens. Such biothreats can harm humans, animals, plants, agriculture, the environment, and materials.

Risks from climate change. Food and feed crops, biofuels crops, and crops used with bio-based fermentation products are susceptible to temperature and water stresses, as well as insects and pathogens that migrate with changing weather patterns.

China: the biotech elephant in the room

I’ve written previously written how the Chinese government is already making substantial investments in its bioeconomy. Here are three scary statistics, courtesy of Greg B. Scott of the ChinaBio Group:

China is out-investing the U.S. China’s private investors poured $14.4 billion into its bioeconomy in 2019. That compares to the United States’ more meager investment of $10.4 billion.

China is building a bigger bioeconomy workforce. China graduates about 8-10 million students each year. In the U.S., that number is closer to 400,000. Many Chinese students graduating from U.S. institutions stay here, but they are increasingly returning home to start highly innovative companies.

China is investing in itself. Historically, China has invested heavily in foreign companies, tech, and debt. Now we’re seeing an uptick in China-to-China investments—the country no longer needs to look abroad to find plenty of good biotech opportunities.

Chinese investments have led to centers of excellence in the regional technology hub of Shenzhen, including the Institute of Synthetic Biology at the Shenzhen Institute of Advanced Sciences (SIAT) and BGI Genomics. Shenzhen will compete for technological and economic leadership with U.S. regional biotech powerhouses such as San Francisco/Silicon Valley and Boston/Cambridge in the years to come.

Many of China’s long-standing challenges—environment, food, water, waste management, and rapid innovation to retain its global manufacturing competitiveness—are areas where synthetic biology is seen as a key technology for the future. In other words, synthetic biology is not just an academic pursuit for China. Rather, its leaders are thinking proactively about how biological engineering can be used to address the country’s strategic national interests—while U.S. leadership stands idly by.

What do we do?

So what can U.S. policymakers do to protect the U.S. bioeconomy and ensure continued technological and economic leadership in biology for the next twenty years?

Straight from the top. China has made clear its ambition to become a global tech superpower, with President Xi Jinping calling science and technology one of the main battlefronts of the economy. The U.S. administration needs to step up its game, too. President Trump recently declared January 2020 to be National Biotechnology Month, citing “boundless possibilities for economic growth, national security, healthcare, manufacturing, and agriculture.” That’s the right sentiment—now we need real action.

New legislation. Late last year, the U.S. House of Representatives passed the Engineering Biology Research and Development Act of 2019, which would direct the Office of Science and Technology Policy (OSTP) to implement a national research strategy for engineering biology. The explicit goal: maintain U.S. science, technology, and economic leadership in synthetic biology. The bill now resides in the Senate and awaits committee action. Legislative leadership is now needed to give this bill the appropriations necessary to give it real teeth, and then put it squarely on the President’s desk.

Investing for returns. The Human Genome Project is said to have returned $141 for every dollar invested by taxpayers. While “Big Science” yields tremendous benefits for everyone, it doesn’t happen without federal funding. In 2019, politically courageous Republicans and Democrats came together to produce a 2020 final spending bill that is kind to science, in essence ignoring President Trump’s proposed cuts and instead giving increases to each of the NIH, NSF, NASA, and DOE’s Office of Science. But the U.S. isn’t even in the top ten for R&D spending as a percentage of GDP, while China continues to close in on the U.S., meaning that the U.S. is no longer the uncontested global leader in science.

Leading the global bioeconomy: Have some courage

There are many things the U.S. could do to protect the American bioeconomy. But above all else, policymakers need to come together and demonstrate the kind of courage and vision needed to be a world leader. Science and technology know no partisan lines. Everybody wants healthy lives, clean water, and good jobs. Federal initiative and assistance are needed to bring these benefits to everyone living in the U.S..

Today, the American synthetic biology industry may be unprepared for the global competition it will face, lacking initiative and leadership at the highest levels of government. But this could change quickly. If a country like the U.S. makes engineering biology a national priority, anything is possible in the new bioeconomy.

#### Heg solves arms races, land grabs, rogue states, and great power war

Brands 18 [Hal, Henry Kissinger Distinguished Professor at Johns Hopkins University's School of Advanced International Studies and a senior fellow at the Center for Strategic and Budgetary Assessments." American Grand Strategy in the Age of Trump." Page 129-133]

Since World War II, the United States has had a military second to none. Since the Cold War, America has committed to having overwhelming military primacy. The idea, as George W. Bush declared in 2002, that America must possess “strengths beyond challenge” has featured in every major U.S. strategy document for a quarter century; it has also been reflected in concrete terms.6

From the early 1990s, for example, the United States consistently accounted for around 35 to 45 percent of world defense spending and maintained peerless global power-projection capabilities.7 Perhaps more important, U.S. primacy was also unrivaled in key overseas strategic regions—Europe, East Asia, the Middle East. From thrashing Saddam Hussein’s million-man Iraqi military during Operation Desert Storm, to deploying—with impunity—two carrier strike groups off Taiwan during the China-Taiwan crisis of 1995– 96, Washington has been able to project military power superior to anything a regional rival could employ even on its own geopolitical doorstep.

This military dominance has constituted the hard-power backbone of an ambitious global strategy. After the Cold War, U.S. policymakers committed to averting a return to the unstable multipolarity of earlier eras, and to perpetuating the more favorable unipolar order. They committed to building on the successes of the postwar era by further advancing liberal political values and an open international economy, and to suppressing international scourges such as rogue states, nuclear proliferation, and catastrophic terrorism. And because they recognized that military force remained the ultima ratio regum, they understood the centrality of military preponderance.

Washington would need the military power necessary to underwrite worldwide alliance commitments. It would have to preserve substantial overmatch versus any potential great-power rival. It must be able to answer the sharpest challenges to the international system, such as Saddam’s invasion of Kuwait in 1990 or jihadist extremism after 9/11. Finally, because prevailing global norms generally reflect hard-power realities, America would need the superiority to assure that its own values remained ascendant. It was impolitic to say that U.S. strategy and the international order required “strengths beyond challenge,” but it was not at all inaccurate.

American primacy, moreover, was eminently affordable. At the height of the Cold War, the United States spent over 12 percent of GDP on defense. Since the mid-1990s, the number has usually been between 3 and 4 percent.8 In a historically favorable international environment, Washington could enjoy primacy—and its geopolitical fruits—on the cheap.

Yet U.S. strategy also heeded, at least until recently, the fact that there was a limit to how cheaply that primacy could be had. The American military did shrink significantly during the 1990s, but U.S. officials understood that if Washington cut back too far, its primacy would erode to a point where it ceased to deliver its geopolitical benefits. Alliances would lose credibility; the stability of key regions would be eroded; rivals would be emboldened; international crises would go unaddressed. American primacy was thus like a reasonably priced insurance policy. It required nontrivial expenditures, but protected against far costlier outcomes.9 Washington paid its insurance premiums for two decades after the Cold War. But more recently American primacy and strategic solvency have been imperiled.

THE DARKENING HORIZON For most of the post–Cold War era, the international system was— by historical standards—remarkably benign. Dangers existed, and as the terrorist attacks of September 11, 2001, demonstrated, they could manifest with horrific effect. But for two decades after the Soviet collapse, the world was characterized by remarkably low levels of great-power competition, high levels of security in key theaters such as Europe and East Asia, and the comparative weakness of those “rogue” actors—Iran, Iraq, North Korea, al-Qaeda—who most aggressively challenged American power. During the 1990s, some observers even spoke of a “strategic pause,” the idea being that the end of the Cold War had afforded the United States a respite from normal levels of geopolitical danger and competition. Now, however, the strategic horizon is darkening, due to four factors.

First, great-power military competition is back. The world’s two leading authoritarian powers—China and Russia—are seeking regional hegemony, contesting global norms such as nonaggression and freedom of navigation, and developing the military punch to underwrite these ambitions. Notwithstanding severe economic and demographic problems, Russia has conducted a major military modernization emphasizing nuclear weapons, high-end conventional capabilities, and rapid-deployment and special operations forces— and utilized many of these capabilities in conflicts in Ukraine and Syria.10 China, meanwhile, has carried out a buildup of historic proportions, with constant-dollar defense outlays rising from US$26 billion in 1995 to US$226 billion in 2016.11 Ominously, these expenditures have funded development of power-projection and antiaccess/area denial (A2/AD) tools necessary to threaten China’s neighbors and complicate U.S. intervention on their behalf. Washington has grown accustomed to having a generational military lead; Russian and Chinese modernization efforts are now creating a far more competitive

## 5

#### Interp – reductions are permanent

Reynolds 59. Judge (In the Matter of Doris A. Montesani, Petitioner, v. Arthur Levitt, as Comptroller of the State of New York, et al., Respondents [NO NUMBER IN ORIGINAL] Supreme Court of New York, Appellate Division, Third Department 9 A.D.2d 51; 189 N.Y.S.2d 695; 1959 N.Y. App. Div. LEXIS 7391 August 13, 1959)

Section 83's counterpart with regard to nondisability pensioners, section 84, prescribes a reduction only if the pensioner should again take a public job. The disability pensioner is penalized if he takes any type of employment. The reason for the difference, of course, is that in one case the only reason pension benefits are available is because the pensioner is considered incapable of gainful employment, while in the other he has fully completed his "tour" and is considered as having earned his reward with almost no strings attached. It would be manifestly unfair to the ordinary retiree to accord the disability retiree the benefits of the System to which they both belong when the latter is otherwise capable of earning a living and had not fulfilled his service obligation. If it were to be held that withholdings under section 83 were payable whenever the pensioner died or stopped his other employment the whole purpose of the provision would be defeated, i.e., the System might just as well have continued payments during the other employment since it must later pay it anyway. The section says "reduced", does not say that monthly payments shall be temporarily suspended; it says that the pension itself shall be reduced. The plain dictionary meaning of the word is to diminish, lower or degrade. The word "reduce" seems adequately to indicate permanency. Aside from the practical aspect indicating permanency other indicia point to the same conclusion. From 1924 (L. 1924, ch. 619) to 1947 (L. 1947, ch. 841) a provision appeared in the Civil Service Law which read substantially as follows: "If the pension of a beneficiary is reduced for any reason, the amount of such reduction shall be transferred from the pension reserve fund to the pension accumulation fund during that period that such reduction is in effect." (See L. 1924, ch. 619, § 2 [Civil Service Law, § 58, subd. 4]; L. 1947, ch. 841 [Civil Service Law, § 66, subd. e].) This provision reappears in the 1955 Retirement and Social Security Law as subdivision f of section 24. This provision is useful for interpretative purposes. Since it prescribes that moneys not paid because of reduction should be transferred back to the accumulation fund the conclusion is inescapable that such reductions were meant to be permanent. If temporary suspensions were intended this bookkeeping device would result in a false picture of the funds, i.e., the reserve fund would be depleted when it would contain adequate funds to meet eventual payments 57\*57 to present pensioners. Likewise, the accumulation fund would be improperly inflated with respect to the present pensioners. Section 64 of the Retirement and Social Security Law (§ 85 under the 1947 act) provides that any disability pension must be reduced by the amount payable pursuant to the Workmen's Compensation Law if applicable. In Matter of Dalton v. City of Yonkers (262 App. Div. 321, 323 [1941]) this court interpreted "reduce" to mean "offset" in holding that under then section 67 (relating to Workmen's Compensation benefits as do its successors sections 85 and 64), pensions were to be offset by compensation benefits. This is merely another indication that "reduce" means a diminishing of the pension pursuant to a given formula rather than a mere recoverable, temporary suspension during the time other benefits or salaries are being received by the pensioner. (Also, cf., Retirement and Social Security Law, § 101 [§ 84 under the 1947 act].)

#### Violation – they don’t defend permancence

#### Negate –

#### Limits and topic lit – their model allows adding on infinite random suspensions to IP protections, anything from conditioning IP protections on human rights to monopolistic tendencies – the core of the debate is reducing IP protections, not temporarily suspending them